CDBT China Dasheng Biotechnology Company (PK)

CUSIP No. 16944C108
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS

 Anna G. Brandt
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 (a) [ ]
 (b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY

--------------------------------------------------------------------------------
4 SOURCE OF FUNDS

 PF
--------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED
 PURSUANT TO ITEMS 2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION

 Canada
--------------------------------------------------------------------------------
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:


 7 SOLE VOTING POWER

 4,300,000
 -------------------------------------------------------
 8 SHARED VOTING POWER

 0
 -------------------------------------------------------
 9 SOLE DISPOSITIVE POWER

 4,300,000
 -------------------------------------------------------
 10 SHARED DISPOSITIVE POWER

 0
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 4,300,000
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)
 EXCLUDES CERTAIN SHARES [ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

 14.3%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*

 IN
--------------------------------------------------------------------------------


ITEM 1. SECURITY AND ISSUER.

 This Schedule 13D relates to the common stock, par value $0.01 (the
"Common Stock"), of China Dasheng Biotechnology Company. (the "Issuer").

 The address of the Issuer's principal executive office is

 China Dasheng Biotechnology Company
 Building B 17th Floor Century Plaza
 Qingyang Road Lanzhou, Gansu
 People's Republic of China

ITEM 2. IDENTITY AND BACKGROUND.

 (a) This statement is being filed by Anna G. Brandt (the
"Reporting Person").

 (b) The principal address for the Reporting Person is
 789 Meadowbrook Lane
 Chambersburg, PA 17201.

 (c) The Reporting Person is an individual investor.

 (d) During the last five years, the Reporting Person has not been
convicted in a criminal proceeding (excluding traffic violations or similar
misdemeanors).

 (e) During the last five years, the Reporting Person has not been a party
to a civil proceeding of a judicial or administrative body of competent
jurisdiction that resulted in the Reporting Person being subject to a judgment,
decree or final order enjoining future violations of, or prohibiting or
mandating activities subject to, federal or state securities laws or finding any
violation with respect to such laws.

 (f) The Reporting Person is a citizen of Canada.

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

 Personal.

ITEM 4. PURPOSE OF TRANSACTION.

Anna G. Brandt may seek a seat on the Company's Board of Directors.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

 The Reporting Person is an individual investor.
4.3 million CDBT shares is 14.3% of the last-reported total outstanding.

The shares were accumulated at an estimated cost-basis
of less than $0.30 per share through open-market purchases.

 SIGNATURE

 After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete, and
correct.

Dated as of: October 31, 2011

 By: /s/ Anna G. Brandt
 ------------------------
 Name: Anna G. Brandt